Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Aquestive Therapeutics Inc shares valued at $310,900 were sold by Jung Cassie on Sep 04 ’25. At $5.00 per share, Jung Cassie sold 62,180 shares. The insider’s holdings dropped to 283,346 shares worth approximately $1.4 million following the completion of this transaction.
Also, Boyd Peter E. sold 15,000 shares, netting a total of over 79,500 in proceeds. Following the sale of shares at $5.30 each, the insider now holds 288,323 shares.
Before that, Boyd Peter E. had added 15,000 shares to its account. In a trade valued at $79,500, the Officer bought Aquestive Therapeutics Inc shares for $5.30 each.
Analysts at Cantor Fitzgerald started covering the stock with ‘”an Overweight”‘ outlook in a report released in mid December. As of May 10, 2024, Leerink Partners has initiated its “an Outperform” rating for AQST. Earlier on April 11, 2024, Piper Sandler initiated its rating. Their recommendation was “an Overweight” for AQST stock.
Analyzing AQST Stock Performance
On last trading session, Aquestive Therapeutics Inc [NASDAQ: AQST] rose 2.28% to $4.94. The stock’s lowest price that day was $4.8145, but it reached a high of $4.96 in the same session. During the last five days, there has been a drop of approximately -0.20%. Over the course of the year, Aquestive Therapeutics Inc shares have dropped approximately -0.40%.
Is Aquestive Therapeutics Inc subject to short interest?
Stocks of Aquestive Therapeutics Inc saw a sharp steep in short interest on 2025-08-29 dropping by -0.17 million shares to 9.27 million. Data from Yahoo Finance shows that the short interest on 2025-07-31 was 9.44 million shares. A decline of -1.81% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 6.79 of the overall float, the days-to-cover ratio (short ratio) decline to 6.79.
Which companies own the most shares of Aquestive Therapeutics Inc (AQST)?
In terms of Aquestive Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 10 in the next 12 months, up nearly 107.04% from the previous closing price of $4.83. Analysts anticipate Aquestive Therapeutics Inc stock to reach 12 by 2025, with the lowest price target being 7. In spite of this, 3 analysts ranked Aquestive Therapeutics Inc stock as Buy at the end of 2025. On March 28, 2024, Raymond James assigned a price target of “an Outperform” to the stock and initiated coverage with a $7.
